ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer

ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer

<0> ADMA Biologics, Inc.Adam S. GrossmanPresident & CEOorBrian Lenz, CPAVice President & Chief Financial Officer201-478-5552 </0>

ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced it has appointed Dr. Mond as its Chief Medical and Scientific Officer, where he will be responsible for strategy and advancing the Company's programs.

"Dr. Mond brings an extensive record of academic and industry clinical and regulatory experience to ADMA, which will be invaluable as we initiate our upcoming Phase III study," said Adam S. Grossman, President and Chief Executive Officer of ADMA. "We are very pleased to welcome him and look forward to his contributions to ADMA's future success."

Dr. Mond has a specific expertise in developing immunological products for the prevention of infectious diseases. Most recently he was Executive Vice President and Chief Scientific Officer of Biosynexus Incorporated where he directed all of the preclinical and clinical trial activities. Prior to joining Biosynexus, Dr. Mond worked as a consultant to Virion Systems Inc. where he oversaw the development of a vaccine technology which the company licensed to GlaxoSmithKline (GSK). These vaccines have been commercialized to prevent pneumococcal infections and meningococcal infections in the pediatric population.

Dr. Mond received his M.D. and Ph.D. degrees from New York University Medical School after which he joined the Laboratory of Immunology under Dr. William Paul at the National Institutes of Health. Dr. Mond has 196 publications in peer reviewed journals and books and has 15 issued patents. He is a practicing board-certified Internist and Rheumatologist and is currently an adjunct Professor of Medicine at the Uniformed Services University of Health Sciences in Bethesda.

RI-001 is a plasma-derived, polyclonal, Intravenous Immune Globulin or IGIV, with standardized high levels of antibodies against Respiratory Syncytial Virus, or RSV. ADMA is pursuing an indication for the use of this IGIV product for treatment of Primary Immunodeficiency Disease, or PIDD. Polyclonal means that the IGIV contains a wide array of antibodies that are obtained from different B-cell resources. Polyclonal antibodies are the primary component of IGIV products. PIDD is a disorder that causes a person's immune system not to function properly. PIDD is caused by hereditary or genetic defects and can affect anyone regardless of age or gender. There are varying types of PIDD ranging from mild to severe cases.

ADMA is a late-stage biotechnology company which focuses its efforts on the development and commercialization of human plasma and plasma-derived therapeutics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted at niche patient populations with unmet medical needs. In addition, ADMA operates ADMA BioCenters, a wholly-owned subsidiary and FDA-licensed source plasma collection facility located in Norcross, Georgia.

This press release contains "forward looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, and commercialization efforts of the Company's product candidate(s). Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks listed under the heading "Risk Factors" in Amendment No. 3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2012 and Amendment No. 3 to our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 3, 2012. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward looking statements or to announce revisions to any of the forward-looking statements.

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.